RPR Lovenox line extensions in 1997 could include two new indications, new packages.

Executive Summary

RPR LOVENOX LINE EXTENSIONS IN 1997 COULD INCLUDE TWO NEW INDICATIONS as well as a new 30 mg ampule and multi-dose vial for the low molecular weight heparin product, Rhone-Poulenc Rorer VP Glenn Mattes told the Bear Stearns health care conference in New York City Sept. 12. Lovenox (enoxaparin) is already marketed for prevention of deep vein thrombosis in hip and knee replacement surgery in packages of 10 prefilled syringes. The company expects approval for use in abdominal surgery "potentially by the end of this year" and hopes for clearance of an indication for treatment of DVT during 1997 as well, Mattes said.